Treatment of Antibody-Mediated Rejection (ABMR) With CarBel (NCT06918990)
Targeting the B Cell Response to Treat Antibody-Mediated Rejection With Carfilzomib and Belatacept (CarBel)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety of carfilzomib and belatacept, administered with steroids and maintenance immunosuppression, in kidney transplant recipients with donor-specific antibody (DSA)-associated graft injury. Participants will be followed for 52 weeks after starting investigational therapy, including protocol biopsies at 3 months and 12 months after start of investigational therapy. The study will also assess changes in immune cell responses, blood and urine biomarkers, and biopsy-based pathomic features associated with antibody-mediated graft injury.
Who can join: Review the eligibility criteria below.
Location: University of Alabama Medical Center (Site # 71136) — Birmingham, Alabama
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- University of Alabama Medical Center (Site # 71136) — Birmingham, Alabama
- Mayo Clinic Arizona (Site # 71144) — Phoenix, Arizona
- UCLA Medical Center (Site #: 71123) — Los Angeles, California
- Northwestern University, Feinberg School of Medicine (Site # 71110) — Chicago, Illinois
- Washington University (Site # 71157) — St Louis, Missouri
- NYU Langone Health (Site # 71177) — New York, New York
- Duke University (Site # 71139) — Durham, North Carolina
- Christ Hospital (Site # 71195) — Cincinnati, Ohio
- University of Cincinnati (Site # 71118) — Cincinnati, Ohio
- Cleveland Clinic (Site # 71101) — Cleveland, Ohio
- University of Wisconsin Madison (Site # 71112) — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (301) 706-9137
Email: ymorrison@niaid.nih.gov
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Kidney Transplant Rejection
- Microbiome and Immunosuppression: The Mission Study — Minneapolis, Minnesota
- Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection — Chicago, Illinois
- The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive) — Birmingham, Alabama
- PROACT Pilot Trial — Vancouver, British Columbia
- AIIM Trial: Personalized Medicine Approach to Kidney Allograft Function — Gainesville, Florida
- Trifecta-Kidney cfDNA-MMDx Study — Tampa, Florida
Explore by condition: All Kidney Transplant Rejection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.